DK3946322T3 - Fremgangsmåder til genoprettelse af sensitivitet over for ttfields i ttfields-resistente kræftceller med ptger3-inhibitorer - Google Patents
Fremgangsmåder til genoprettelse af sensitivitet over for ttfields i ttfields-resistente kræftceller med ptger3-inhibitorer Download PDFInfo
- Publication number
- DK3946322T3 DK3946322T3 DK20717971.4T DK20717971T DK3946322T3 DK 3946322 T3 DK3946322 T3 DK 3946322T3 DK 20717971 T DK20717971 T DK 20717971T DK 3946322 T3 DK3946322 T3 DK 3946322T3
- Authority
- DK
- Denmark
- Prior art keywords
- ttfields
- ptger3
- restoration
- inhibitors
- sensitivity
- Prior art date
Links
- 101001117517 Homo sapiens Prostaglandin E2 receptor EP3 subtype Proteins 0.000 title 1
- 102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 title 1
- 230000035945 sensitivity Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826078P | 2019-03-29 | 2019-03-29 | |
| US201962849535P | 2019-05-17 | 2019-05-17 | |
| PCT/IB2020/052959 WO2020201967A1 (en) | 2019-03-29 | 2020-03-27 | Methods for restoring sensitivity to ttfields in ttfields-resistant cancer cells with ptger3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3946322T3 true DK3946322T3 (da) | 2023-11-27 |
Family
ID=70228406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20717971.4T DK3946322T3 (da) | 2019-03-29 | 2020-03-27 | Fremgangsmåder til genoprettelse af sensitivitet over for ttfields i ttfields-resistente kræftceller med ptger3-inhibitorer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11911610B2 (da) |
| EP (3) | EP3988099B1 (da) |
| JP (2) | JP7419391B2 (da) |
| CN (1) | CN113613651A (da) |
| DK (1) | DK3946322T3 (da) |
| PL (1) | PL3946322T3 (da) |
| WO (1) | WO2020201967A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10779875B2 (en) | 2013-05-06 | 2020-09-22 | Novocure Gmbh | Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment |
| US10188851B2 (en) | 2015-10-28 | 2019-01-29 | Novocure Limited | TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements |
| US10821283B2 (en) | 2016-04-04 | 2020-11-03 | Novocure Gmbh | Reducing motility of cancer cells using tumor treating fields (TTFields) |
| CN110178029B (zh) | 2017-01-19 | 2021-11-16 | 诺沃库勒有限责任公司 | 用于在施加TTFields的同时在显微镜下观察细胞培养物的系统 |
| US11986647B2 (en) | 2018-09-07 | 2024-05-21 | Novocure Gmbh | Treating autoinflammatory and mitochondrial diseases using an alternating electric field |
| US11154707B2 (en) | 2018-10-15 | 2021-10-26 | Novocure Gmbh | Generating tumor treating fields (TTFields) with high uniformity throughout the brain |
| PL3922301T3 (pl) | 2018-11-19 | 2024-06-10 | Novocure Gmbh | Szyki do dostarczania zmiennych pól elektrycznych do leczenia nowotworów (ttfields) z selektywnie adresowalnymi pod-elementami |
| EP3886978B1 (en) | 2018-11-29 | 2024-04-03 | Novocure GmbH | Enhanced-flexibility transducer arrays for delivering ttfields (tumor treating fields) |
| EP3909015A1 (en) | 2019-01-08 | 2021-11-17 | Novocure GmbH | Evaluating quality of segmentation of an image into different types of tissue for planning treatment using tumor treating fields (ttfields) |
| US11654279B2 (en) | 2019-07-31 | 2023-05-23 | Novocure Gmbh | Applying tumor treating fields (TTFields) via electrodes embedded into skull implants |
| JP2022545794A (ja) | 2019-08-30 | 2022-10-31 | ノボキュア ゲーエムベーハー | 頸部への腫瘍治療電界（ＴＴＦｉｅｌｄｓ）の印加 |
| DK4074367T3 (da) | 2019-12-31 | 2023-05-22 | Novocure Gmbh | Arrays til levering af tumorbehandlingsfelter (tt-felter) med individuelt tilgængelige elektrodeelementer og temperatursensorer |
| IL294284A (en) | 2019-12-31 | 2022-08-01 | Novocure Gmbh | A high-voltage, high-efficiency sine wave generator that prevents jumps when adjusting amplitude and changing channels |
| US11818943B2 (en) | 2020-06-25 | 2023-11-14 | Novocure Gmbh | Fabricating organic light emitting diodes (OLEDs) using tubulin |
| US20220267445A1 (en) * | 2021-02-17 | 2022-08-25 | Novocure Gmbh | Methods and Compositions for Determining Susceptibility to Treatment with Checkpoint Inhibitors |
| WO2024062456A1 (en) | 2022-09-23 | 2024-03-28 | Novocure Gmbh | 3d models for predicting treatment responses to alternating electric fields |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7089054B2 (en) | 2002-10-02 | 2006-08-08 | Standen Ltd. | Apparatus and method for treating a tumor or the like |
| US6868289B2 (en) | 2002-10-02 | 2005-03-15 | Standen Ltd. | Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor |
| US8447395B2 (en) | 2000-02-17 | 2013-05-21 | Novocure Ltd | Treating bacteria with electric fields |
| US7016725B2 (en) | 2001-11-06 | 2006-03-21 | Standen Ltd. | Method and apparatus for destroying dividing cells |
| WO2001060994A1 (en) | 2000-02-17 | 2001-08-23 | Palti Yoram Prof | Method and apparatus for destroying dividing cells |
| US7136699B2 (en) | 2002-10-02 | 2006-11-14 | Standen, Ltd. | Apparatus for destroying dividing cells |
| US7599746B2 (en) | 2000-02-17 | 2009-10-06 | Standen Ltd | Apparatus and method for preventing the spread of cancerous metastases and for elimination of metastases |
| US8175698B2 (en) | 2000-02-17 | 2012-05-08 | Novocure Ltd. | Treating bacteria with electric fields |
| CA2563817C (en) | 2004-04-23 | 2018-07-10 | Yoram Palti | Treating a tumor or the like with electric fields at different frequencies |
| CA2590342C (en) | 2004-12-07 | 2016-09-20 | Standen Ltd. | Electrodes for applying an electric field in-vivo over an extended period of time |
| EP1833554A2 (en) | 2004-12-27 | 2007-09-19 | Standen Ltd. | Treating a tumor or the like with electric fields at different orientations |
| PT1933937E (pt) | 2005-10-03 | 2015-04-23 | Novocure Ltd | Optimização de características de um campo eléctrico para aumentar o efeito do campo em células proliferantes |
| US8019414B2 (en) | 2006-04-05 | 2011-09-13 | Novocure Ltd. | Treating cancer using electromagnetic fields in combination with other treatment regimens |
| US20100074896A1 (en) | 2006-11-30 | 2010-03-25 | The Johns Hopkins University | Antagonists of pge2 ep3 receptors |
| ES2629612T3 (es) | 2007-03-06 | 2017-08-11 | Novocure Ltd. | Tratamiento del cáncer usando campos electromagnéticos en combinación con terapia fotodinámica |
| WO2009022225A1 (en) | 2007-08-14 | 2009-02-19 | Novocure Ltd. | Treating parasites with electric fields |
| US8715203B2 (en) | 2007-09-17 | 2014-05-06 | Novocure Limited | Composite electrode |
| JP5730854B2 (ja) | 2009-04-06 | 2015-06-10 | 大塚製薬株式会社 | デシタビンとシチジンデアミナーゼ阻害剤との組合せ、およびがんの治療におけるその使用 |
| US9381176B2 (en) | 2012-02-24 | 2016-07-05 | Wisconsin Alumni Research Foundation | E-prostanoid receptor, Ptger3, as a novel anti-diabetic therapeutic target |
| US10779875B2 (en) | 2013-05-06 | 2020-09-22 | Novocure Gmbh | Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment |
| US9655669B2 (en) | 2013-05-06 | 2017-05-23 | Novocure Limited | Optimizing treatment using TTFields by changing the frequency during the course of long term tumor treatment |
| US20190117963A1 (en) | 2014-07-25 | 2019-04-25 | Loyalty Based Innovations, LLC | Apparatus and method for treating multiple tumors in patients with metastatic disease by electric fields |
| US9910453B2 (en) | 2015-09-25 | 2018-03-06 | Novocure Limited | High voltage, high efficiency sine wave generator with pre-set frequency and adjustable amplitude |
| US10188851B2 (en) | 2015-10-28 | 2019-01-29 | Novocure Limited | TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements |
| US10821283B2 (en) | 2016-04-04 | 2020-11-03 | Novocure Gmbh | Reducing motility of cancer cells using tumor treating fields (TTFields) |
| WO2018002879A1 (en) | 2016-06-30 | 2018-01-04 | Zeev Bomzon | Arrays for longitudinal delivery of ttfields to a body |
| CA2972699A1 (en) | 2016-07-10 | 2018-01-10 | Novocure Limited | Synchronizing tumor cells to the g2/m phase using ttfields combined with taxane or other anti-microtubule agents |
| BR112019003199A2 (pt) | 2016-08-18 | 2019-06-18 | Novocure Ltd | medição de temperatura em array para entrega do tt fields |
| KR102548188B1 (ko) | 2016-12-13 | 2023-06-27 | 지브 봄존 | 전극위치가 변형 가능한 템플릿들로 최적화된 종양 치료장을 이용하여 환자들을 치료 |
| CN110178029B (zh) | 2017-01-19 | 2021-11-16 | 诺沃库勒有限责任公司 | 用于在施加TTFields的同时在显微镜下观察细胞培养物的系统 |
| TWI676483B (zh) | 2017-08-06 | 2019-11-11 | 強普生技股份有限公司 | 醫藥套組及其用途 |
| WO2019197973A1 (en) | 2018-04-09 | 2019-10-17 | Moshe Giladi | Treating tumors with ttfields and an aurora kinase inhibitor |
| WO2019197999A1 (en) | 2018-04-10 | 2019-10-17 | Zeev Bomzon | Low frequency (<1 mhz) ac conductivity estimates derived from two mri images having different repetition times |
| US11529511B2 (en) | 2018-07-03 | 2022-12-20 | The Board Of Trustees Of The Leland Stanford Junior University | Using alternating electric fields to increase cell membrane permeability |
| US11179322B2 (en) | 2018-07-10 | 2021-11-23 | Novocure Gmbh | Methods and compositions for treating tumors with TTFields and sorafenib |
| US11911612B2 (en) | 2018-07-18 | 2024-02-27 | Novocure Gmbh | Using power loss density and related measures to quantify the dose of tumor treating fields (TTFields) |
| PL3892219T3 (pl) | 2018-08-23 | 2022-10-03 | Novocure Gmbh | Zastosowanie przemiennych pól elektrycznych w celu zwiększenia przepuszczalności bariery krew-mózg |
| US11160977B2 (en) | 2018-09-04 | 2021-11-02 | Novocure Gmbh | Delivering tumor treating fields (TTFields) to the infratentorial brain |
| WO2020049482A1 (en) | 2018-09-07 | 2020-03-12 | Yaniv Alon | Treating autoimmune diseases using an alternating electric field to reduce the proliferation of t-cells |
| US20200108031A1 (en) | 2018-10-05 | 2020-04-09 | Novocure Gmbh | Treating Tumors Using TTFields Combined with ABT-751 |
| WO2020086753A1 (en) | 2018-10-23 | 2020-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention and treatment of teratoma formation in stem cell-based thereapies using alternating electric fields |
| EP3870271A1 (en) | 2018-10-25 | 2021-09-01 | Zeev Bomzon | Delivering alternating electric fields (e.g., ttfields) to a subject's spinal anatomy |
| US20200146586A1 (en) | 2018-11-14 | 2020-05-14 | Novocure Gmbh | Creating Accurate Computational Head Models of Patients Using Datasets Combining MRI and CT Images |
| PL3922301T3 (pl) | 2018-11-19 | 2024-06-10 | Novocure Gmbh | Szyki do dostarczania zmiennych pól elektrycznych do leczenia nowotworów (ttfields) z selektywnie adresowalnymi pod-elementami |
| EP3886978B1 (en) | 2018-11-29 | 2024-04-03 | Novocure GmbH | Enhanced-flexibility transducer arrays for delivering ttfields (tumor treating fields) |
| EP3909015A1 (en) | 2019-01-08 | 2021-11-17 | Novocure GmbH | Evaluating quality of segmentation of an image into different types of tissue for planning treatment using tumor treating fields (ttfields) |
-
2020
- 2020-03-27 EP EP21208101.2A patent/EP3988099B1/en active Active
- 2020-03-27 EP EP20717971.4A patent/EP3946322B1/en active Active
- 2020-03-27 EP EP21208102.0A patent/EP3977991A1/en active Pending
- 2020-03-27 CN CN202080026046.4A patent/CN113613651A/zh active Pending
- 2020-03-27 US US16/832,572 patent/US11911610B2/en active Active
- 2020-03-27 DK DK20717971.4T patent/DK3946322T3/da active
- 2020-03-27 JP JP2021554764A patent/JP7419391B2/ja active Active
- 2020-03-27 PL PL20717971.4T patent/PL3946322T3/pl unknown
- 2020-03-27 WO PCT/IB2020/052959 patent/WO2020201967A1/en unknown
-
2023
- 2023-10-04 JP JP2023172824A patent/JP2023171933A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200306531A1 (en) | 2020-10-01 |
| CN113613651A (zh) | 2021-11-05 |
| EP3988099A1 (en) | 2022-04-27 |
| EP3946322A1 (en) | 2022-02-09 |
| WO2020201967A1 (en) | 2020-10-08 |
| US11911610B2 (en) | 2024-02-27 |
| EP3988099B1 (en) | 2023-06-07 |
| JP2023171933A (ja) | 2023-12-05 |
| JP7419391B2 (ja) | 2024-01-22 |
| EP3946322B1 (en) | 2023-09-20 |
| EP3988099C0 (en) | 2023-06-07 |
| JP2022524824A (ja) | 2022-05-10 |
| PL3946322T3 (pl) | 2024-02-26 |
| EP3977991A1 (en) | 2022-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3946322T3 (da) | Fremgangsmåder til genoprettelse af sensitivitet over for ttfields i ttfields-resistente kræftceller med ptger3-inhibitorer | |
| DK3523326T3 (da) | Samstimulerende domæner til anvendelse i genetisk modificerede celler | |
| DK3827838T3 (da) | Hæmning af cytokin-induceret sh2-protein i nk-celler | |
| DK3453065T3 (da) | Reaktor med avanceret arkitektur til elektrokemisk reduktion af cox | |
| DK2880447T3 (da) | Markører forbundet med følsomhed for hæmmere af human double minute 2 (MDM2) | |
| DK2970890T3 (da) | Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller | |
| DK3594340T3 (da) | Sammensætninger og fremgangsmåder til samling med høj nøjagtighed af nukleinsyrer | |
| DK3594348T3 (da) | Kort c/ebp-alpha til aktivering af rna-sammensætninger og anvendelsesfremgangsmåder | |
| DK3084119T3 (da) | Fremgangsmåde til indstilling af niveauet af inhibitorer i en olie- eller gasbrønd | |
| DK2978419T3 (da) | Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf | |
| DK2968290T3 (da) | Transient beskyttelse af normale celler under kemoterapi | |
| DK3328414T3 (da) | Sammensætning til anvendelse i fremme af sårheling | |
| EA201171396A1 (ru) | Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата | |
| DK2994742T3 (da) | Fremgangsmåde og indretning til realtidsmåling af varmeværdier af brændgassammensætninger | |
| DK2663864T3 (da) | Fremgangsmåde til at vurdere immundiversitet og anvendelse af denne | |
| DK3068776T3 (da) | Inhibitorer af replikation af influenzavira | |
| DK2971037T3 (da) | Temperaturændring til ekspression med højt udbytte af polypeptider i gær og andre transformerede celler | |
| CO7020907A2 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos | |
| DK2825175T3 (da) | Rho-kinase-inhibitorer til anvendelse i behandling af amyotrofisk lateral sklerose | |
| DK3519074T3 (da) | Skivefilter af rammetypen med kontrol af bypassvand for at forhindre anvendelsen af bypassvand til returskylning | |
| DK3768284T3 (da) | Sammensætninger af enterococcus flagellin til anvendelse i terapi | |
| DK2950800T3 (da) | Fremgangsmåder og sammensætninger til daglig ophthalmisk administration af phentolamin til forbedring af synsevnen | |
| EA201491568A1 (ru) | Совместное применение ингибитора кластерина и ингибитора egfr для лечения рака | |
| DK3064575T3 (da) | Fremgangsmåde til differentiering af pluripotent stamcelle induceret fra mesenkymal stamcelle til hepatocyt | |
| DK3454907T3 (da) | Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation |